Patents by Inventor Corey M. REEVES

Corey M. REEVES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ascaroside derivatives and methods of use
    Patent number: 11845770
    Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
    Type: Grant
    Filed: October 21, 2022
    Date of Patent: December 19, 2023
    Assignees: California Institute of Technology, Holoclara, Inc.
    Inventors: Brian M. Stoltz, Corey M. Reeves, Eduardo J. Martinez, Simon Bailey
  • ASCAROSIDE DERIVATIVES AND METHODS OF USE
    Publication number: 20230135574
    Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
    Type: Application
    Filed: October 21, 2022
    Publication date: May 4, 2023
    Inventors: Brian M. Stoltz, Corey M. Reeves, Eduardo J. Martinez, Simon Bailey
  • MCL1 INHIBITORS AND USES THEREOF
    Publication number: 20230116602
    Abstract: The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 13, 2023
    Inventors: Brendan M. O' Boyle, Emma L. Baker-Tripp, Corey M. Reeves, Kevin C. Yang, Tristin E. Rose, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • ASCAROSIDE DERIVATIVES AND METHODS OF USE
    Publication number: 20220235086
    Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
    Type: Application
    Filed: May 15, 2020
    Publication date: July 28, 2022
    Inventors: Brian M. Stoltz, Corey M. Reeves, Eduardo J. Martinez, Simon Bailey
  • KRAS G12C INHIBITORS AND USES THEREOF
    Publication number: 20220227738
    Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 21, 2022
    Inventors: Justin A. Hilf, Tristin E Rose, Michael D. Bartberger, Brendan M. O'Boyle, Corey M. Reeves, Oliver C. Loson, Brian M. Stoltz, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20220194949
    Abstract: The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 23, 2022
    Inventors: Brendan M. O'Boyle, Corey M. Reeves, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Steven J. Wittenberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20220002294
    Abstract: The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 6, 2022
    Inventors: Corey M. Reeves, Brandan M. O'Boyle, Justin A. Hilf, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Steven J. Wittenberger, Oliver C. Loson, Michael D. Bartberger, Brian M. Stoltz
  • Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
    Patent number: 10246429
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: April 2, 2019
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, James A. Brown, Ning Chen, Michael J. Frohn, Longbin Liu, Qingyian Liu, Liping H. Pettus, Wenyuan Qian, Corey M. Reeves, Aaron C. Siegmund
  • VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    Publication number: 20180222876
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, James A. BROWN, Ning CHEN, Michael J. FROHN, Longbin LIU, Qingyian LIU, Liping H. PETTUS, Wenyuan QIAN, Corey M. REEVES, Aaron C. SIEGMUND